Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 07/30/18

Staff, Pictures and Bios

Jeff Moscow, MD, Branch Chief

Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in January 2014 after serving part time since August 2012. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…

S. Percy Ivy, MD, Associate Branch Chief, IDB

S. Percy Ivy, MD, is the Associate Chief (2005-present) of the Investigational Drug Branch (IDB), which is part of the Cancer Therapy Evaluation Program (CTEP) in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute. She received her medical and subspecialty training at Tulane University Medical School, Vanderbilt University Medical Center, and the National Cancer Institute, respectively. More…

John J. Wright, MD, PhD, Associate Branch Chief, IDB

Dr. Wright received a PhD in molecular virology from the University of Illinois Medical Center and his medical degree from Northwestern University Medical School in Chicago. He completed internship and residency training in Internal Medicine at the University of Virginia in Charlottesville. He then was a research fellow in the Metabolism Branch of the National Cancer Institute. More…

Helen Chen, MD, Associate Branch Chief, IDB

Dr. Helen Chen joined the Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI) in 2000. She currently serves as Associate Chief of the Investigational Drug Branch (IDB) Section III, which focuses on the clinical development of antibody-based therapeutics, active immunotherapies, MAPK and RTK inhibitors as well as antiangiogenic agents. More…

Fernanda I. Arnaldez, MD, Physician

Fernanda Arnaldez, MD, joined the Investigational Drug Branch, CTEP, in 2017 as a Physician in the Investigational Therapeutics 1 Section where she develops clinical trials within the CTEP portfolio. In addition, she is the Scientific Officer for the Experimental Therapeutics Clinical Trials Network (ETCTN) and the Early Drug Development Opportunity Program (EDDOP) Coordinator. Her background includes oncology research in government, industry and academia. More…

Austin Doyle, MD, Physician

Dr. Doyle received his medical degree from the University of Maryland School of Medicine, where he completed internship and residency training in Internal Medicine. Dr. Doyle completed a medical oncology fellowship in the NCI-Navy Medical Oncology Branch of NCI. More…

Charles Kunos, MD, PhD, Physician

Dr. Charles Kunos joined CTEP in 2016. He received his MD and PhD from Case Western Reserve University School of Medicine. Subsequently, he served as the Clinical Director of the Gynecologic, Pediatric, and Musculoskeletal Radiation Therapy service lines in the Department of Radiation Oncology at University Hospitals of Cleveland and Assistant Professor in the Department of Radiation Oncology at Case Western Reserve University. In this capacity, he was responsible for delivering teletherapy in the clinic and brachytherapy in the clinic and the operating room. He developed skills in helical tomotherapy, gamma knife radiosurgery, and Cyberknife stereotactic body radiosurgery. More…

Richard Piekarz, MD, PhD, Physician

Dr. Piekarz is a Medical Officer in the Investigational Therapeutics 2 Section of the Investigational Drug Branch of CTEP. Dr. Piekarz is a graduate of the Albert Einstein College of Medicine, where he received a PhD in Molecular Pharmacology in addition to an MD. He did his internship and residency in Internal Medicine at the University Hospitals of Cleveland. More…

Elad Sharon, MD, MPH, Physician

Dr. Sharon joined CTEP in December 2011 as a Senior Investigator in the Investigational Drug Branch, where he works with academic investigators and industry collaborators to carry out the clinical development of promising new cancer therapies. His current portfolio includes immunotoxins, antibody-drug conjugates, immune-based monoclonal antibodies and other targeted agents. Dr. Sharon received his M.D. from Baylor College of Medicine in Houston, Texas in 2003. More…

Minkyung (Min) Song, Ph.D., Program Director

Dr. Song fosters, manages, oversees and analyzes the NCI portfolio on multidisciplinary, translational and clinical research grants and cooperative agreements for Clinical trials of chemotherapy, immunotherapy, cellular therapy, gene therapy, radiation therapy, surgery, or their combinations, and associated correlative studies. More…

Howard Streicher, MD, Physician

Dr Streicher received AB in physics from Cornell University and his medical degree from New York University. He completed an internship and residency training in Internal Medicine at the New York University-Bellevue Medical Center and New York Veterans Hospital. More…

Kim Witherspoon, Senior Program Specialist, Biologist

Ms. Kim Witherspoon has been a part of the Cancer Therapy Evaluation Program (CTEP) since September 2000. She became part CTEPís Investigational Drug Branch (IDB) in February 2018. In IDB, Kim ensures compliance with NIH and NCI grant policy. She is Senior Program Specialist for the Experimental Therapeutics Clinical Trials Network (ETCTN). She performs duties as a Program Official, a Level II FAC-Contract Officer's Representative (COR), and Program Analyst. As a Program Official, her portfolio includes clinical research projects focused on bioethics. More…

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in January 2014 after serving part time since August 2012. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…